Endo International (NASDAQ:ENDP) (TSE:ENL) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.15-2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.86. The company issued revenue guidance of $2.6-2.8 billion, compared to the consensus revenue estimate of $3.03 billion.
A number of research firms have recently issued reports on ENDP. Cantor Fitzgerald cut their price objective on Endo International from $9.00 to $7.00 and set a neutral rating for the company in a research report on Friday, November 10th. ValuEngine cut Endo International from a buy rating to a hold rating in a research report on Friday, February 2nd. B. Riley began coverage on Endo International in a research report on Wednesday, February 14th. They issued a buy rating and a $10.00 price objective for the company. BidaskClub raised Endo International from a sell rating to a hold rating in a research report on Tuesday, December 12th. Finally, Barclays cut their price objective on Endo International from $15.00 to $10.00 and set an equal weight rating for the company in a research report on Friday. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $10.32.
Shares of Endo International (NASDAQ ENDP) opened at $6.84 on Tuesday. The firm has a market capitalization of $1,531.93, a P/E ratio of -0.30, a P/E/G ratio of 2.40 and a beta of 0.29. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $14.45.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.